Dilaudid, Exalgo (hydromorphone) dosing, indications, interactions, adverse effects, and more. Contraindications. Hypersensitivity. Dilaudid Liquid and Tablets. Suppository. Increased intracranial pressure resulting from intracranial lesion; conditions resulting in depressed ventilatory function including COPD, emphysema, status asthmaticus, kyphoscoliosis, cor pulmonale. Dilaudid injection Dilaudid HP: Paralytic ileus, opioid nontolerant patients, known ro suspected pre- existing GI surgery or diseases resulting in narrowing of GI tract loops in the GI tract or GI obstruction. Dilaudid HP is contraindicated in non- opioid tolerant patients Extended- release (Exalgo) Opioid nontolerant patients. Paralytic ileus, opioid nontolerant patients, known ro suspected pre- existing GI surgery or diseases resulting in narrowing of GI tract loops in the GI tract or GI obstruction. Significant respiratory depression. Acute or severe bronchial asthma Cautions. May impair physical or mental abilities; use caution when performing work that require mental alertness such as operating machinery or driving. Myoclonus and seizures reported with high doses; use caution in patients with history of seizure disorders. Use with caution in patients with hypersensitivity reactions to other phenanthrene derivative opioid agonists, including codeine, hydrocodone, levorphanol, oxycodone, oxymorphone. May cause hyptension especially in patients with cardiovascular disease or hypovolemia; may cause severe hyptension, including orthostatic hypotension and syncope; use caution in patients taking drugs that may exagerate hypotensive effects, including phenothiazines or general anesthetics; avoid use in patients with circultory shock; may reduce cardiac output and blood pressure. May prevent diagnosis of patients with acute abdominal conditions. Use caution in patients with biliary tract dysfunction. Use cautioin in patients with inflammatory or obstructive bowel disorder, acute pancreatitis secondary to biliary tract disease, and patients undergoing biliary surgery. Use with caution in patients with adrenal insufficiency including Addison's disease. Avoid use in patients susceptible to intracranial effects of CO2 retention including CNS depression or coma. Carbon dioxide retention from opioid- induced respiratory depression can exacerbate sedating effects of opioids. Use cuation in delirium tremens. Long- term opioid use may cause secondary hypogonadism, which may lead to sexual dysfunction, infertility, mood disorders, and osteoporosis. High potential for abuse; use caution in patients with history of drug abuse or alcoholism. Caution when coadministered with other CNS depressents (eg, barbiturates, benzodiazepines, alcohol)Use caution in renal/hepatic impairment, obesity, prostatic hyperplasia/urinary stricture, psychoses, respiratory disease or thyroid dysfunction. Wow, I don't know what I was trying to say when I said, 'The really bad is that lie all opiates, Dilaudid is very addictive;' hehehe. But really, the Dilaudid is very. As an RN I can tell you that dilaudid or hyromorphone is known as hospital herorin. I don’t want to you to frighten you but is important for you to know with what. Use within 1. 4 days of MAO intake not recommended. Controlled- release formulation should only be used when continuous analgesia is required over an extended period of time; not for use PRNIM formulation may result in variable absorption and a lag time to peak effect. RATING: REASON: SIDE EFFECTS FOR PHENERGAN: COMMENTS: SEX: AGE: DURATION/ DOSAGE: DATE ADDED F M : 5: Nausea: Tired the next day, droggy next day. My guess is that you are on to low of a fentanyl dosage, compared to your oxycontin (oxyneo is the same I think) and percocet dosage. They have conversion charts. First, the usual disclaimer; Everyone is different and reacts to medications differently. What works for one person may not necessarily work the same for another. Pain Management- Interventional Kyphoplasty/Vertebroplasty (with vertebral fractures) Epidural and caudal steroid injections (neck, back pain). Tailor opioid- containing analgesic regimen to each patient's needs. May cause constipation; consider preventive measures to reduce potential of constipation; use with caution in patients with chronic constipation. Use caution in patients with head injury, intracranial lesions, or elevated intracranial pressure; exagerated intracranial pressure may occur with treatment. Use caution in patients who are morbidly obese. Some formulations may contain lactose; consider lactose content prior to initiating therapy in patients with hereditary disease of galatose intolerance. Vial stoppers of single- dose injectable vials may contain latex. Some dosage forms may contain trace amounts of sodium metabisulfite, which may cause allergic reactions. Use of opioid agonists/antagonists my cause withdrawal symptoms. Long- acting opioids. Schedule II opioid analgesics expose users to the risks of addiction, abuse, and misuse; there is a greater risk for overdose and death with extended- release opioids due to the larger amount of active opioid present (see Black Box Warnings)Addiction, abuse, and misuse risks are increased in patients with a personal or family history of substance abuse or mental illness (eg, major depression); the potential for these risks should not, however, prevent the prescribing of proper pain management in any given patient; intensive monitoring is necessary (see Black Box Warnings)Serious, life- threatening, or fatal respiratory depression reported (see Black Box Warnings). Accidental exposure reported, including fatalities (see Black Box Warnings)Neonatal opioid withdrawal syndrome reported with long- term use during pregnancy (see Black Box Warnings)Interactions with CNS depressants (eg, alcohol, sedatives, anxiolytics, hypnotics, neuroleptics, other opioids) can cause additive effects and increase risk for respiratory depression, profound sedation, and hypotension. Life- threatening respiratory depression is more likely to occur in elderly, cachectic, or debilitated patients as they may have altered pharmacokinetics or altered clearance compared to younger, healthier patients. Controlled release MS Contin. Doses over 1. 60. Patients receiving other oral morphine. Avinza. Usual: 1. IV/SC continuous infusion: 0. Titrate to. response. Usual range: up to 8. Epidural: Start 5 mg in lumbar region. If inadequate relief. Max: 1. 0 mg/2. 4 hours. Intrathecal (1/1. Repeat doses. are not recommended.
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. Archives
January 2017
Categories |